ArticleInternational journal of surgery (London, England)2026
Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer: a multicenter retrospective cohort study.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis multicenter real-world study aimed to evaluate the efficacy, safety, and neoadjuvant trastuzumab and pertuzumab combined with different chemotherapy regimens in Chinese patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
methodsA retrospective analysis was conducted on 557 patients treated at 15 institutions in China between January 2019 and December 2021. Patients were divided into three groups based on chemotherapy regimens: EC-THP (epirubicin, cyclophosphamide, docetaxel/paclitaxel protein-bound, trastuzumab, pertuzumab), TCbHP (docetaxel/paclitaxel protein-bound, carboplatin, trastuzumab, pertuzumab), and THP (docetaxel/paclitaxel protein-bound, trastuzumab, pertuzumab).The primary endpoint was total pathological complete response (tpCR), defined as the absence of invasive disease in both the breast and axillary lymph nodes (ypT0/is, ypN0). Secondary endpoints included axillary pCR (ypN0), breast pCR (ypT0/is), and safety. Propensity score overlap weighting was applied to minimize confounding factors.
resultsOf the 557 patients included in the study, 341 (61.2%) achieved tpCR. The tpCR rate was significantly higher in the HER2-positive hormone receptor (HR)-negative group (183/242 patients, 75.6%) than in the HER2-positive HR-positive group (158/315 patients, 50.2%, P < 0.001), as well as bpCR was achieved in 188/241 patients (77.7%) in the HER2-positive HR-negative group compared to 164/315 patients (52.1%) in the HER2-positive HR-positive group ( P < 0.001), and apCR was achieved in 214/242 patients (88.4%) vs. 240/315 patients (76.2%), respectively ( P < 0.001). After applying propensity score overlap weighting, no significant differences were observed among the three treatment regimen groups in tpCR (68.4% vs. 63.0% vs. 54.5%, P = 0.116), bpCR (71.3% vs. 64.0% vs. 59.6%, P = 0.198), or apCR (80.2% vs. 84.4% vs. 73.9%, P = 0.173). Gene analysis suggested favorable tpCR trends in patients with TP53, ERBB2, MYC, or CCND1 alterations, though not statistically significant. Most adverse events were grades 1-2, with anemia (254/557, 45.6%), leukopenia (147/557, 26.4%), and reduced ejection fraction (99/421, 23.4%) being the most common. No fatal toxicities were reported.
conclusionsTrastuzumab and pertuzumab combined with different chemotherapy regimens demonstrated high tpCR rates and manageable safety in HER2-positive breast cancer, particularly in HER2-positive HR-negative patients. The study supports the real-world efficacy of dual HER2-targeted neoadjuvant therapy, though further validation of biomarkers and long-term outcomes is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.